EU to disburse the remaining MSEK 4.7 of the Horizon grant
Idogen AB (publ) develops tolerogenic cell therapies to treat conditions or illnesses that are caused by an adverse immune response. The EU has approved the final report of the Horizon 2020 project for development of tolerogenic cell therapies, and the company has thus received the remaining MSEK 4.7. In May 2017, Idogen was granted research funding of MEUR 2.86 (just over MSEK 29) from Horizon 2020 (the EU Framework Program for Research and Innovation) to develop the company’s tolerogenic cell therapy, developed for the treatment of patients with severe hemophilia who have